Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with metabolic syndrome parameters in Malaysian subjects

Journal of Clinical Biochemistry and Nutrition

Volumn 50, Issue 3, 2012, Pages 184-189

  Al Hamodi, Zaid H ^a   Saif Ali, Riyadh ^a,b   Ismail, Ikram S ^c   Ahmed, Khaled A ^d   Muniandy, Sekaran ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b Department of Biochemistry   (Yemen)

^c UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^d IBB UNIVERSITY   (Yemen)

Author keywords

Cardiovascular disease; Metabolic syndrome; Plasminogen activator inhibitor 1; Tissue plasminogen activator; Type 2 diabetes

Indexed keywords

GLUCOSE; INSULIN; LIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; BIOCHEMISTRY; BODY MASS; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE BLOOD LEVEL; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MALAYSIA; MALE; METABOLIC SYNDROME X; NORMAL HUMAN; PROTEIN BLOOD LEVEL;

EID: 84860756332     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.11-48     Document Type: Article

References (45)

1. Al-Hamodi Z, Ismail IS, Saif-Ali R, Ahmed KA, Muniandy S. Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects. Cardiovasc Diabetol 2011; 10: 23.
2. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428. (Pubitemid 40523737)
3. Zimmet PA, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787. (Pubitemid 34000780)
4. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006; 26: 2200-2207. (Pubitemid 44465712)
5. Anna Ågren. Mechanisms and effects of low plasminogen activator inhibitor type 1 activity. Stockholm: Published by Karolinska Institutet, 2008.
6. Dellas C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 2005; 93: 631-640. (Pubitemid 40485397)
7. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792-1801. (Pubitemid 30390240)
8. Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005; 3: 35-45. (Pubitemid 41647113)
9. Lopes C, Dina C, Durand E, Froguel P. PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population. Diabetologia 2003; 46: 1284-1290. (Pubitemid 37214987)
10. Juhan-Vague I, Morange PE, Frere C, et al. The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH study. J Thromb Haemost 2003; 1: 2322-2329.
11. Mansfield MW, Stickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 1995; 74: 842-847.
12. Freeman MS, Mansfield MW. To: Hoffsted et al. (2002) The common -675 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is strongly associated with obesity. Diabetologia 2002; 45: 1602-1603 author reply 1604.
13. Hoffstedt J, Andersson IL, Persson L, Isaksson B, Amer P. The common -675 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is strongly associated with obesity. Diabetologia 2002; 45: 584-587. (Pubitemid 34533839)
14. Viitanen L, Pihlajamäki J, Halonen P, et al. Association of angiotensin converting enzyme and plasminogen activator inhibitor-1 promoter gene polymorphisms with features of the insulin resistance syndrome in patients with premature coronary heart disease. Atherosclerosis 2001; 157: 57-64. (Pubitemid 32539354)
15. Tishkoff SA, Ruano G, Kidd JR, Kidd KK. Distribution and frequency of a polymorphic Alu insertion at the plasminogen activator locus in humans. Hum Genet 1996; 97: 759-764. (Pubitemid 26150845)
16. Novick GE, Novick CC, Yunis J, et al. Polymorphic Alu insertions and the Asian origin of Native American populations. Hum Biol 1998; 70: 23-39. (Pubitemid 28091516)
17. van den Eijnden-Schrauwen Y, Lakenberg N, Emeis JJ, de Knijff P. Alu-repeat polymorphism in the tissue-type plasminogen activator (tPA) gene does not affect basal endothelial tPA synthesis. Thromb Haemost 1995; 74: 1202.
18. Alessi MC, Poggi M, Juhan-Vague I. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Curr Opin Lipidol 2007; 18: 240-245. (Pubitemid 46743045)
19. Kang BY, Lee KO. Genetic polymorphisms of t-PA and PAI-1 genes in the Korean population. Korean J Biol Sci 2003; 7: 249-253.
20. Alberti KG, Zimmet P, Shaw J and IDF Epideminology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366: 1059-1062.
21. Anvari A, Schuster E, Gottsauner-Wolf M, Wojta J, Huber K. PAI-I 4G/5G polymorphism and sudden cardiac death in patients with coronary artery disease. Thromb Res 2001; 103: 103-107. (Pubitemid 32701947)
22. Margaglione M, Cappucci G, Colaizzo D, et al. The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Arterioscler Thromb Vasc Biol 1998; 18: 152-156. (Pubitemid 28277590)
23. Jastrzebska M, Goracy I, Naruszewicz M. Relationships between fibrinogen, plasminogen activator inhibitor-1, and their gene polymorphisms in current smokers with essential hypertension. Thromb Res 2003; 110: 339-344. (Pubitemid 37329836)
24. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-10745. (Pubitemid 23162248)
25. Grancha S, Estellés A, Tormo G, et al. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease. Thromb Haemost 1999; 81: 516-521. (Pubitemid 29178933)
26. Burzotta F, Di Castelnuovo A, Amore C, et al. 4G/5G promoter PAI-1 gene polymorphism is associated with plasmatic PAI-1 activity in Italians: a model of gene-environment interaction. Thromb Haemost 1998; 79: 354-358. (Pubitemid 28065884)
27. Eriksson P, Kallin B, van 't Hooft FM, Båvenholm P, Hamsten A. Allelespecific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851-1855.
28. Schneiderman J, Sawdey MS, Keeton MR, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89: 6998-7002.
29. Lo HS, Wang Z, Hu Y, et al. Allelic variation in gene expression is common in the human genome. Genome Res 2003; 13: 1855-1862. (Pubitemid 36987191)
30. Palacios R, Gazave E, Goni J, et al. Allele-specific gene expression is widespread across the genome and biological processes. PLoS One 2009; 4: e4150.
31. Pant PV, Tao H, Beilharz EJ, Ballinger DG, Cox DR, Frazer KA. Analysis of allelic differential expression in human white blood cells. Genome Res 2006; 16: 331-339. (Pubitemid 43327503)
32. Sternlicht MD, Dunning AM, Moore DH, et al. Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiol Biomarkers Prev 2006; 15: 2107-2114. (Pubitemid 44877033)
33. Jeng JR. Association of PAI-1 gene promoter 4G/5G polymorphism with plasma PAI-1 activity in Chinese patients with and without hypertension. Am J Hypertens 2003; 16: 290-296.
34. Loskutoff DJ, Sawdey M, Keeton M, Schneiderman J. Regulation of PAI-1 gene expression in vivo. Thromb Haemost 1993; 70: 135-137. (Pubitemid 23225465)
35. Roncal C, Orbe J, Rodriguez JA, et al. Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension. Cardiovasc Res 2004; 63: 176-185. (Pubitemid 38759823)
36. Hoekstra T, Geleijnse JM, Schouten EG, Kluft C. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost 2004; 91: 861-872. (Pubitemid 38647488)
37. Perusse L, Despres JP, Lemieux S, Rice T, Rao DC, Bouchard C. Familial aggregation of abdominal visceral fat level: results from the Quebec family study. Metabolism 1996; 45: 378-382. (Pubitemid 26102645)
38. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563. (Pubitemid 16177394)
39. Thogersen AM, Jansson JH, Boman K, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98: 2241-2247. (Pubitemid 28533841)
40. Ye Z, Liu EH, Higgins JP, et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006; 367: 651-658. (Pubitemid 43289155)
41. Tsantes AE, Nikolopoulos GK, Bagos PG, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of ischemic stroke: a meta-analysis. Blood Coagul Fibrinolysis 2007; 18: 497-504. (Pubitemid 46975954)
42. Tsantes AE, Nikolopoulos GK, Bagos PG, et al. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis. A meta-analysis. Thromb Haemost 2007; 97: 907-913. (Pubitemid 46939203)
43. Boekholdt SM, Bijsterveld NR, Moons AH, Levi M, Buller HR, Peter RJ. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation 2001; 104: 3063-3068. (Pubitemid 34014058)
44. Suzuki J, Ogawa M, Muto S, et al. Effects of specific chemical suppressors of plasminogen activator inhibitor-1 in cardiovascular diseases. Expert Opin Investig Drugs 2011; 20: 255-264.
45. Wang B, Zhou X, Dang A, Liu G, He R. Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator and the risk of hypertension in a Chinese Han population. Hypertens Res 2002; 25: 949-953. (Pubitemid 36024653)